Phase III is the last stage

Phase III is the last stage, ‘ or treatment receives FDA approval. The UroCenter the first, the first site in the nation by the FDA to participate in the study, the patients can enroll in immediately. ‘Our goal to give the patient as many treatment options as possible, said Dr . Walter Rayford, principal investigator and urologist at the UroCenter. ‘Obtain with HIFU, patients advanced care, while the highest possible quality of life. ‘.

Moreover, theUroCenter to participate in prostate cancer clinical trialThe UroCenter, a partnership between Baptist Memorial Healthcare and the doctors of UroCenter is the first site in the nation by the Food and Drug Administration for a Phase III study for a non – invasive therapy that uses ultrasound technology localized localized prostate cancer treatment.

Bruce mentioned that the African-Americans in the study, the risk factors, increased body mass index and higher frequency of low blood iron, and higher pressures to the brain as a non – African Americans participants were, and that these factors could partial account to the increased risk of loss of vision. This much on the European market, passed the required tests and are already want from a number of hospitals to avoid them completely, the health problems and uncertainties about plasticizers. Employed for over 60 European hospitals in PVC phase-out projects, there is a reasonable likelihood that the EU will be made ​​reports of DEHP and alternative plasticizers are redundant from a market shift towards alternative materials, driven by hospitals with patient care relevant questions instead of protecting their industry sales of PVC medical devices.

MEA News & Events


MedEd Architects announced the launch of a series of on-going educational programs specifically targeted to reach as many as 2.6 million Chinese physicians. The series includes live symposia and web-based programs developed in partnership with renowned US -based medical centers and leading Chinese medical societies. Programs will be accessed through a branded web portal designed to generate awareness of new treatment choices among Chinese physicians.